Exelixis (EXEL) Short-term Investments (2010 - 2026)
Exelixis (EXEL) posted quarterly Short-term Investments of $551.1 million for Q2 2026, down 34.98% year-over-year from $847.6 million in Q2 2025, and down 4.43% quarter-over-quarter from $576.6 million in Q1 2026.
Analysis
Exelixis (EXEL) Short-term Investments (2010 - 2026) Analysis & Trends
Exelixis' Short-term Investments history runs 17 years deep, the most recent figure standing at $551.1 million for Q2 2026.
- In Q2 2026, Short-term Investments fell 34.98% year-over-year to $551.1 million; the TTM figure through Apr 2026 stood at $551.1 million (down 34.98% YoY), while the FY2026 annual figure was $576.6 million, down 35.5% from the prior year.
- Short-term Investments for Q2 2026 stood at $551.1 million, down from $576.6 million in the prior quarter.
- The five-year high for Short-term Investments was $930.8 million in Q3 2024, with the low at $551.1 million in Q2 2026.
- The 5-year median for Short-term Investments is $802.3 million (2023), against an average of $764.3 million.
- The sharpest annual moves came in 2024 and 2026: Short-term Investments jumped 31.74% in 2024, then sank 35.5% in 2026.
- Exelixis' Short-term Investments stood at $807.3 million in 2022, then decreased by 9.29% to $732.3 million in 2023, then grew by 27.11% to $930.8 million in 2024, then plunged by 34.23% to $612.2 million in 2025, then retreated by 9.99% to $551.1 million in 2026.
- Business Quant data shows EXEL's Short-term Investments at $551.1 million in Q2 2026, $576.6 million in Q1 2026, and $612.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 557.94 Mn |
| Apr 3, 2026 | 551.06 Mn |
| Jan 2, 2026 | 576.60 Mn |
| Oct 3, 2025 | 612.24 Mn |
| Jul 4, 2025 | 626.67 Mn |
| Apr 4, 2025 | 847.56 Mn |
| Jan 3, 2025 | 893.90 Mn |
| Sep 27, 2024 | 930.82 Mn |
| Jun 28, 2024 | 803.54 Mn |
| Mar 29, 2024 | 703.70 Mn |
| Dec 29, 2023 | 732.31 Mn |
| Sep 29, 2023 | 706.53 Mn |
| Jun 30, 2023 | 802.34 Mn |
| Mar 31, 2023 | 772.54 Mn |
| Dec 30, 2022 | 807.27 Mn |
| Sep 30, 2022 | 871.71 Mn |
| Jul 1, 2022 | 907.94 Mn |
| Apr 1, 2022 | 847.06 Mn |
| Dec 31, 2021 | 819.91 Mn |
| Oct 1, 2021 | 835.41 Mn |